VRSK - Tudor Investment opens new Seagen AbbVie bets; exits Immersion Lennox

2023-11-15 12:30:18 ET

Tudor Investment, the hedge fund founded by billionaire Paul Tudor Jones, started new positions in Seagen ( NASDAQ: SGEN ), with 340K shares, AbbVie ( NYSE: ABBV ), with 157.3K shares, and Verisk Analytics ( NASDAQ: VRSK ), with 80.2K shares, during the third quarter, according to its latest 13F filing.

The firm boosted its stakes in Nvidia ( NASDAQ: NVDA ) to 178.7K from 40.6K, Horizon Therapeutics ( HZNP ) to 1.26M from 1.08M, Goldman Sachs ( NYSE: GS ) to 115.2K from 3.92K, and Chevron ( NYSE: CVX ) to 245.0K from 205.5K.

It closed out its holdings in Immersion Corp. ( NASDAQ: IMMR ) and Lennox International ( NYSE: LII ).

Reduced stakes in Medtronic ( NYSE: MDT ) to 301.5K from 359.7K, C3.ai ( NYSE: AI ) to 721.2K from 742.6K, and CME Group ( NASDAQ: CME ) to 111.6K from 117.4K, the filing showed.

More on 13F Filings

• Tracking Baillie Gifford's 13F Portfolio - Q3 2023 Update
• David Tepper's Appaloosa exits Apple, Marvell, Broadcom in Q3
• Michael Burry closes out broad market shorts, bets against semis

For further details see: